

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: M. Alexandra Glucksmann *et al.*

Serial No.: N/A

Filed: Herewith

For: 14273 RECEPTOR, A NOVEL G-PROTEIN
COUPLED RECEPTOR

Attorney Docket No.: MNI-204CP2DV2

Group Art Unit: 1646

Examiner: Brannock, M.

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: February 13, 2002

Mailing Label Number: EL 892 199 445 US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Larry Taylor
Name of Person Mailing Paper


Signature of Person Mailing Paper

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination of the above-identified application, please amend the application as follows:

In the claims:

Please cancel claims 1-23, without prejudice, and add new claims 24-44 as follows:

24. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a cell expressing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

25. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a cell expressing a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

26. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is binding to a G protein in response to ligand binding.

27. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is G protein phosphorylation in response to ligand binding.

28. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is binding to a ligand.

29. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of intracellular calcium concentration.

30. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of intracellular cAMP concentration.

31. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of adenylate cyclase activity.

32. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of phospholipase C activity.

10075987 021302 200120 18562001

33. The method of any one of claims 24 or 25, wherein said cell is a cardiac myocyte.
34. The method of any one of claims 24 or 25, wherein modulation of a 14273 polypeptide activity by the test compound is detected by detecting a morphological change in said cell.
35. The method of claim 34, wherein said morphological change is cellular hypertrophy.
36. The method of any one of claims 24 or 25, wherein said test compound is a peptide.
37. The method of any one of claims 24 or 25, wherein said test compound is an antibody.
38. The method of any one of claims 24 or 25, wherein said test compound is a small molecule.
39. The method of any one of claims 24 or 25, wherein said compound stimulates a 14273 polypeptide activity.
40. The method of any one of claims 24 or 25, wherein said compound inhibits a 14273 polypeptide activity.
41. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:
 - a) contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
 - b) detecting modulation of a 14273 polypeptide activity by the test compound.
42. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:
 - a) contacting a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment

20250807 021302

thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and

b) detecting modulation of a 14273 polypeptide activity by the test compound.

43. The method of any one of claims 41 or 42, wherein said 14273 polypeptide activity is binding to a G protein

44. The method of any one of claims 41 or 42, wherein said 14273 polypeptide activity is binding to a ligand.

REMARKS

Claims 1-23 were pending in the present application. Claims 1-23 have been canceled, without prejudice, and new claims 24-44 have been added. Accordingly, upon entry of the present amendment, claims 24-44 will be pending. For the Examiner's convenience, the currently pending claims are set forth herein in Appendix A.


Support for new claims 24-44 can be found throughout the specification including the claims as originally filed. Specifically, support for these claims may be found at, for example, page 29, line 25, through page 32, line 29.

No new matter has been added. Any amendments to and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite the prosecution of the application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

CONCLUSION

In view of the amendments and remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Maria C. Laccotripe, Ph.D.
Attorney for Applicant
Limited Recognition Under 37 C.F.R. §10.9(b)

28 State Street
Boston, Massachusetts 02109
telephone: (617) 227-7400
facsimile: (617) 742-4214
Date: February 13, 2002

1005987 021302

APPENDIX A

24. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a cell expressing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

25. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a cell expressing a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

26. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is binding to a G protein in response to ligand binding.

27. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is G protein phosphorylation in response to ligand binding.

28. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is binding to a ligand.

29. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of intracellular calcium concentration.

30. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of intracellular cAMP concentration.

31. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of adenylate cyclase activity.

10075987 021302

32. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of phospholipase C activity.
33. The method of any one of claims 24 or 25, wherein said cell is a cardiac myocyte.
34. The method of any one of claims 24 or 25, wherein modulation of a 14273 polypeptide activity by the test compound is detected by detecting a morphological change in said cell.
35. The method of claim 34, wherein said morphological change is cellular hypertrophy.
36. The method of any one of claims 24 or 25, wherein said test compound is a peptide.
37. The method of any one of claims 24 or 25, wherein said test compound is an antibody.
38. The method of any one of claims 24 or 25, wherein said test compound is a small molecule.
39. The method of any one of claims 24 or 25, wherein said compound stimulates a 14273 polypeptide activity.
40. The method of any one of claims 24 or 25, wherein said compound inhibits a 14273 polypeptide activity.
41. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:
- contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
 - detecting modulation of a 14273 polypeptide activity by the test compound.

10075987 024302

42. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

43. The method of any one of claims 41 or 42, wherein said 14273 polypeptide activity is binding to a G protein

44. The method of any one of claims 41 or 42, wherein said 14273 polypeptide activity is binding to a ligand.

10076987 021309